RA
GLUE icon

Royce & Associates’s Monte Rosa Therapeutics GLUE Stock Holding History

Royce & Associates’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,024
Closed -$81.7K – 784
2025
Q3 		$81.7K Buy
11,024
+848
+8% +$4.49K ﹤0.01% 755
2025
Q2 		$45.9K Buy
+10,176
New +$45.4K ﹤0.01% 780

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Royce & Associates's GLUE Position: Q4 2025 in Review

Royce & Associates sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 11,024 shares — an estimated $81.7K sold.

Royce & Associates first reported a position in GLUE in Q2 2025 and held it in 2 quarters. The position peaked at $81.7K in Q3 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Royce & Associates reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Royce & Associates sold 11,024 Monte Rosa Therapeutics shares in Q4 2025, an estimated $81.7K.
  • Royce & Associates first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 2 quarters.
  • Royce & Associates's Monte Rosa Therapeutics position peaked at $81.7K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Royce & Associates's 13F filing for Q4 2025, filed 9 Feb 2026.